aTYR PHARMA INC (ATYR) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-15

Key Insights

aTyr Pharma announced Q1 2026 financial results on May 15, 2026, with the full details contained in the press release (Exhibit 99.1) which is not included in this 8-K filing summary.
The company is trading on the Nasdaq Capital Market under ticker ATYR and maintains its Delaware incorporation with headquarters in San Diego, California.
As a non-emerging growth company, aTyr Pharma is subject to full SEC compliance requirements and cannot utilize extended transition periods for new accounting standards.

Want the newest filings?

This analysis covers the filing from 2026-05-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-11

aTyr has $68.3 million in cash and equivalents as of March 31, 2026, providing a substantial runway for continued development of efzofitimod in pulmonary sarcoidosis.
The FDA's feedback resulted in a redesigned Phase 3 trial using FVC as primary endpoint and KSQ-Lung as secondary endpoint, with increased dosing frequency from once every 4 weeks to once every 3 weeks, representing a meaningful pivot from the prior EFZO-FIT study design.
The new Phase 3 trial will enroll up to 372 patients with restrictive lung disease (FVC ≤80% predicted), focused on a narrower patient population based on positive signals from the prior trial showing a 124 ml FVC difference in this subgroup.
Enhanced safety monitoring including anti-synthetase syndrome surveillance and a data safety monitoring committee reflects regulatory concerns that must be addressed, with IND submission planned for June 2026.

Filed: 2026-03-05

aTyr Pharma reported its full-year 2025 financial results, providing investors with an update on the company's operational and financial performance.
The company did not provide any forward-looking guidance or commentary on future product development or regulatory milestones, which could be a concern for investors looking for visibility into the company's pipeline and growth prospects.
The lack of any major business updates or news in this 8-K filing suggests the company may be in a relatively stable, ongoing operational phase without significant near-term catalysts.

Other reports for aTYR PHARMA INC

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.